Pulmonx Corporation released an investor presentation outlining its focus on treating severe emphysema with the Zephyr Valve, a minimally invasive endobronchial valve designed to reduce hyperinflation by allowing trapped air to escape from a diseased lung lobe while preventing re-entry. The presentation describes the patient selection workflow using the StratX CT-based analysis to identify eligible lobes and the Chartis System to assess collateral ventilation, followed by bronchoscopic valve placement and a minimum three-night hospital stay for monitoring. The company cites evidence from four randomized trials comparing Zephyr Valves with medical management in Chartis-confirmed patients and notes more than 40,000 total patients treated and over 100 scientific publications. It also summarizes reimbursement and coding in the U.S., estimates a global market opportunity of about $12 billion for severe emphysema, and highlights an investigational AeriSeal System intended to expand eligibility by addressing collateral ventilation status. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulmonx Corporation published the original content used to generate this news brief on March 04, 2026, and is solely responsible for the information contained therein.
Comments